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Background: Glial cell activation and overproduction of inflammatory mediators in the central nervous system
(CNS) have been implicated in acute traumatic injuries to the CNS, including spinal cord injury (SCI). Elevated
levels of the proinflammatory cytokine tumor necrosis factor (TNF), which exists in both a soluble (sol) and a
transmembrane (tm) form, have been found in the lesioned cord early after injury. The contribution of solTNF
versus tmTNF to the development of the lesion is, however, still unclear.
Methods: We tested the effect of systemically or centrally blocking solTNF alone, using XPro1595, versus using the
drug etanercept to block both solTNF and tmTNF compared to a placebo vehicle following moderate SCI in mice.
Functional outcomes were evaluated using the Basso Mouse Scale, rung walk test, and thermal hyperalgesia analysis. The
inflammatory response in the lesioned cord was investigated using immunohistochemistry and western blotting analyses.
Results: We found that peripheral administration of anti-TNF therapies had no discernable effect on locomotor
performances after SCI. In contrast, central administration of XPro1595 resulted in improved locomotor function,
decreased anxiety-related behavior, and reduced damage to the lesioned spinal cord, whereas central administration
of etanercept had no therapeutic effects. Improvements in XPro1595-treated mice were accompanied by increases in
Toll-like receptor 4 and TNF receptor 2 (TNFR2) protein levels and changes in Iba1 protein expression in microglia/
macrophages 7 and 28 days after SCI.
Conclusions: These studies suggest that, by selectively blocking solTNF, XPro1595 is neuroprotective when applied
directly to the lesioned cord. This protection may be mediated via alteration of the inflammatory environment without
suppression of the neuroprotective effects of tmTNF signaling through TNFR2.
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Spinal cord injury (SCI) is a devastating clinical condition
often resulting in paralysis below the level of injury and
the development of secondary complications such as
chronic pain and autonomic dysreflexia [1]. Broadly
speaking, the primary injury is mediated by an initial
traumatic event to the cord resulting in neuronal and* Correspondence: klambertsen@health.sdu.dk; jrb445@drexel.edu
†Equal contributors
1Department of Neurological Surgery, The Miami Project to Cure Paralysis,
University of Miami Miller School of Medicine, 1095 NW 14th Ter R-48, Miami,
FL 33136, USA
6Department of Biology, Drexel University, 3245 Chestnut St., PISB 123,
Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article
© 2014 Novrup et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.glial injury/death and disruption of the blood-spinal cord
barrier at the epicenter, which is almost immediately
followed by a secondary wave of neuronal and gliatoxic
sequelae including a rapid increase in glutamate, immuno-
regulatory cytokines such as tumor necrosis factor (TNF),
toxic lipid metabolites, and, over time, the infiltration
of peripheral blood leukocytes such as neutrophils,
macrophages, and T-cells [2]. The immune system plays
a dual role in both pathological destruction of neuronal
tissue as well as in tissue repair and to some extent
functional recovery [3-11]. Understanding the dichotomy
between tissue destruction and tissue repair is essentialLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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other neurodegenerative disorders.
TNF is a pleiotropic cytokine important in the
regulation of numerous physiological and pathological
processes such as inflammation, autoimmunity, neu-
rodegeneration, neuroprotection, demyelination, and
remyelination [9,12-18]. There are two active forms of
TNF, soluble-TNF (solTNF) and transmembrane-TNF
(tmTNF), whose biological responses are primarily
mediated by two distinct receptors, TNFR1 and TNFR2,
respectively. TNFR1 has a death domain and signaling
through this receptor has been implicated in both
neuronal and oligodendrocyte death [9,15,17,19], whereas
signaling through TNFR2 has been implicated in neuro-
protection and remyelination [9,20,21]. Expression studies
demonstrate that TNF is upregulated in the spinal cord
within minutes to hours following injury and coincides
with elevated glutamate, suggesting that injury-induced
cytotoxicity may be mediated through additive or syner-
gistic interactions between these and other soluble factors
[2,10]. Studies using genetically engineered mice lacking
either TNFR1 or TNFR2 show that TNF and its receptors
indeed play a role in functional recovery and pathology
following SCI [22]. While the behavioral data are difficult
to interpret because the Basso, Beattie, and Bresnahan test
was applied to evaluate changes in locomotor function in
mice; the histological data are clear, deleting TNFR1
significantly reduces tissue damage [22]. In support of these
studies, mice lacking TNFR1 (TNFR1−/−), the receptor
preferentially activated by solTNF, are protected from
experimental allergic encephalomyelitis (EAE) – a mouse
model of multiple sclerosis – and have reduced pathology
and normal remyelination [21,23,24]. Conversely, mice
lacking TNF (TNF−/−) or TNFR2 (TNFR2−/−), the primary
receptor for tmTNF, have worse functional outcome and
do not remyelinate when exposed to EAE. Studies using
genetically modified mice expressing only tmTNF show
that this form of the cytokine, signaling through TNFR2,
is sufficient to suppress the induction and progression
of EAE [25]. Finally, we and others recently determined
that systemic delivery of a selective inhibitor of solTNF,
XPro1595, which binds solTNF forming inactive hetero-
dimers [26], significantly improves functional recovery,
reduces axonal damage, and promotes remyelination. In
contrast, inhibition of solTNF and tmTNF with the non-
specific TNF inhibitor, etanercept (decoy TNFR2 which
blocks solTNF, tmTNF, and lymphotoxin [27]), proved
neither therapeutic nor neuroprotective in EAE [9,20].
Based upon these and other data, we sought to investi-
gate whether a pharmacological inhibition of solTNF or
total TNF was therapeutic following SCI. Our results
suggest that selectively targeting solTNF directly in the
cord may be a new therapeutic avenue for this clinically
devastating condition.Materials and methods
Mice
Adult, female C57BL/6 mice were purchased from Charles
River (USA) and transferred to The Miami Project to Cure
Paralysis, University of Miami Miller School of Medicine,
Miami, FL, USA, or from Taconic Ltd. (Ry, Denmark) and
transferred to the Biomedical Laboratory, University of
Southern Denmark, Odense, Denmark. Mice were housed
in virus/antigen-free environments under diurnal lightning
conditions and allowed free access to food and water. All
experiments were approved by the University of Miami
Animal Care and Use Committee (#09-010) and the Danish
Animal Inspectorate (2008/561-1526).
Induction of spinal cord injury
Surgeries were performed at the Animal and Surgical Core
Facility of the Miami Project to Cure Paralysis or at the
Biomedical Laboratory, University of Southern Denmark.
Mice were anaesthetized using a ketamine (100 mg/kg,
VEDCO Inc., Saint Joseph, MO, USA)/xylazine (10 mg/kg,
VEDCO) cocktail, laminectomized between vertebrae T8
and T10, and the impactor lowered at a predetermined
impact force resulting in an approximate displacement of
500 μm (moderate injury). Contusion injury was induced
with the mouse Infinite Horizon-0400 SCI Contusion
Device (Precision Systems and Instrumentation, LLC,
Fairfax Station, VA, USA) [3].
Sham-lesioned mice were subjected to laminectomy
without displacement of the spinal cord and otherwise
treated exactly like SCI-lesioned mice.
For central administration, micro-osmotic pumps were
administered (see below) and mice were sutured and
injected s.c. with 1 mL lactated Ringer’s Fluid USP (B.
Braun, L7502, Bethlehem, PA, USA) to prevent dehydra-
tion, and housed separately in a recovery room, where their
post-surgical health status was observed during a 24 to
48 h recovery period. Thereafter, mice were observed twice
daily for activity level, body temperature, respiratory rate,
and general physical condition. Manual bladder expression
was performed twice a day until bladder function was
regained. Body weight was monitored weekly. In addition,
mice received s.c. prophylactic injections of antibiotic
gentamicin (40 mg/kg) for 7 days following SCI to prevent
urinary tract infections.
Drug treatment
Immediately after surgery, mice were implanted with a
micro-osmotic pump (Alzet model 1003D, Durect Cor-
poration, Cupertino, CA, USA), which, for a period of
3 days, continuously delivered epidurally either XPro1595
(2.5 mg/mL concentration/1 μL/h), etanercept (Enbrel,
2.5 mg/mL/1 μL/h), or saline control (0.9% physiological
saline/1 μL/h). Treatment dose was determined based on
previous publications [28,29]. Stainless steel cannulas
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tubes and linked to the Alzet pumps, which were installed
in subcutaneous pockets on the lateral back of the mice.
Methylcyano acrylate was used to affix the catheters to
T10, and wounds were closed with sutures.
Groups consisted of mice surviving either 7 (n = 12–
15/group), 28 (n = 4–6/group), or 35 days (n = 14/group).
Separate groups of mice were subjected to sham surgery
and were allowed to recover from surgery for the 3 days
that the micro-osmotic pumps delivered saline (n = 3),
XPro1595 (n = 3), or etanercept (n = 3).
In order to test the efficacy of an alternative adminis-
tration route, in a separate experiment we injected groups
of mice s.c. with saline (n = 12), 10 mg/kg XPro1595
(n =12), or 10 mg/kg etanercept (n = 12). Treatment dose
was determined based on previous publications [9,20,30].
First injection was performed 30 min after SCI, followed
by s.c. injections every 3 days for 8 weeks. Time points
of administration were based on previous findings of
significantly elevated levels of TNF in the spinal cord
within the first hour after SCI [10,31].
Behavioral analysis
Basso Mouse Scale
Functional recovery of function after SCI was determined
by scoring of the locomotor hind limb performance in the
open field using the Basso Mouse Scale (BMS) system, a 0
to 9 rating system designed specifically for mice [3,32].
Under observer blinded conditions, mice were evaluated
over a 4-min period, 1 and 3 days after SCI and weekly
thereafter. Only mice with a score below 2 on day 1 were
included in the study. Before surgery, mice were handled
and pre-trained in the open field to prevent fear and/or
stress behaviors that could bias the locomotor assessment.
Catwalk
The Catwalk test was performed, as described previously,
to assess gait and motor coordination of mice [33]. The
Catwalk equipment and software were purchased from
Noldus Information Technology (Leesburg, VA, USA).
Briefly, the mice continuously walked along a glass floor
1 m in length. Two fluorescent lamps that ran along
the bottom of the floor illuminated the points of contact
between the paws and floor. A video camera located
beneath the glass floor recorded the gait of the mice. Each
animal performed three runs. The following parameters
were analyzed using the purchased software: the stride
length, the base of support, paw contact area, and the
intensity (assigned by the software) of the paw print.
Gridwalk
The grid walk was performed to analyze fine motor control.
The grid consisted of steel rods (2 mm in diameter) that
were spaced either 5 or 10 mm apart for a total distance of1 m. The mice continuously walked along the rods. The
number of slips for the hind leg was counted. One run
was considered as back and forth, allowing for counting
of the number of slips by both hind legs. Each mouse
performed three runs. The number of slips over the three
runs was averaged. The behavioral test was performed
once a week on each animal. The placement of the
rods was changed each week to prevent the mice from
performing on “memory”.
Rung walk
In order to test stepping, inter-limb coordination, and
balance, mice were tested on the rung walk when they
reached a BMS score of 5. The rung walk consisted of
two plates of transparent polymer, approximately 110 cm×
20 cm, with a 2.5 cm space between them. Rungs with a
2 mm diameter were placed using a specific pattern
according to Metz and Whishaw [34]. The apparatus was
placed on two cages with the home cage at one end,
making the mice automatically walk in that direction.
To avoid stopping or turning during trials, animals were
pre-trained five times prior to surgery with the final test
serving as baseline. Following SCI, mice were tested at 3,
4, and 5 weeks using a handheld GoPro HD camera with
48 fps. Data were evaluated frame by frame using Quick-
Time. Left and right scores were calculated as follows: 6,
complete miss; 5, touching rung, but sliding off and losing
balance; 4, touch, miss but no loss of balance; 3, replace-
ment, mouse placed paw on rung but quickly moves it; 2,
recorrection, aims for a rung but changes direction; 1,
anterior or posterior placement; 0, perfect step. The total
number of mistakes was plotted for analysis as previously
described by Metz and Whishaw [34].
Thermal hyperalgesia
Thermal hyperalgesia (hind paw withdrawal from a
normally innocuous heat source) was tested with a
Hargreave’s heat source as described in detail by Berrocal
et al. [35] (systemic studies) or by using the Plantar Test
apparatus (37370, Ugo Basile, Comerio VA, Italy) (central
studies). For peripherally administered studies, the test
was repeated on the opposite paw and repeated two more
times. In between each measurement, the mouse was
allowed to recover for 15 min. The latency times of three
measurements per foot were averaged. For the centrally
administrated studies, each paw was tested five times with
at least 2 min break in between. The lowest and highest
reflex latency scores of each paw were discarded and the
bilateral mean was calculated and plotted. The behavioral
test was performed once a week on each animal.
Open field
The open field test was performed with a non-transparent,
squared plastic box (45 × 45 × 45 cm) over a period of
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video tracking software (Panlab, Barcelona, Spain) con-
nected to a video camera (SSC-DC378P, Biosite, Stockholm,
Sweden). The distance travelled (m), speed (cm/sec), and
the entries into the three zones (wall, interperiphery, and
center of the box) were recorded automatically. Rearing,
grooming, urination, and droppings were recorded manu-
ally and are presented as number (n) of events.
Tissue processing
Histopathology and immunohistochemistry
For paraffin histopathology and immunohistochemical
analysis, mice were deeply anaesthetized using an over-
dose of pentobarbital (200 mg/mL) containing lidocaine
(20 mg/mL) and perfused through the left ventricle with
cold phosphate buffered saline (PBS) followed by 4%
paraformaldehyde in PBS. The spinal cords were quickly
removed and tissue segments containing the lesion area
(1 cm centered on the lesion) were paraffin-embedded
and cut into 10 parallel series of 15-μm thick microtome
sections. Sections were stored at room temperature until
further processing. For mice with 8 weeks survival and
treated s.c. with anti-TNF, spinal cords were cryoprotected
in 0.1 M PBS + 20% sucrose and cut into 10 series of
25-μm thick cryostat sections and stored at −80°C until
further processing.
Klüver-Barrera Luxol Fast Blue staining for myelinated fibers
For evaluation of lesion pathology, sections were stained
in Luxol Fast Blue (0.1% Luxol Fast Blue in 95% EtOH
and 0.05% acetic acid) at 60°C overnight. The next day,
sections were rinsed in 96% EtOH and distilled H2O,
immersed briefly in 0.05% Li2CO3 in distilled water, and
differentiated in 70% EtOH. Next, sections were rinsed
thoroughly in distilled H2O and immersed in 0.05%
Li2CO3 to stop further differentiation. Sections were
then placed in hematoxylin, rinsed in running tap water,
and immersed briefly in eosin solution. Finally, sections
were rinsed in 70% EtOH, followed by 95% and 99%
EtOH, placed in 2 × xylene prior to mounting with
Depex. Prior to staining, paraffin embedded sections were
deparaffinized 3 × 3 min in xylene, 3 × 2 min in 99%
EtOH, and 2 × 2 min in 96% EtOH.
Determination of injury volume
The injury volume was determined from the area of every
tenth section sampled by systematic uniform random
sampling. The area of the lesion site was estimated
essentially as described by Bethea et al. [10].
Digital images were acquired using the 4× lens on an
Olympus BX51 microscope fitted with an Olympus DP70
digital camera and a computerized specimen stage (Prior,
Multicontrol 2,000 MW). The setup was connected to a
PC running Visiopharm Integrator Software (Visiopharma/s, Hørsholm, Denmark) for image analysis. Calibrated
digital images of the sampled sections were acquired and
subjected to semi-automatic segmentation in VisioMorph
(Visiopharm a/s) in a multistep protocol: 1) labelling of
the entire tissue section based on thresholding (× <59) in
the green channel with (5.5) media filtering; 2) labelling
of all myelinated fibers based on thresholding (× <90)
in a channel created by subtracting the red channel
information from the blue channel information, followed
by (5.5) media filtering; 3) post-processing to remove
small objects; 4) outlining of the lesion area by drawing; 5)
outlining of intact grey matter by drawing; 6) automated
calculation of the areas belonging to A) lesion, B) intact
grey matter, C) myelinated fibers, and D) total section
area. These areas were summarized and multiplied by the
section distance, resulting in an estimate of the total
volumes after dehydration and paraffin embedding.
Western blotting
Spinal cords of mice used for western blotting included
the following groups: naive mice (n = 3), saline-treated
SCI mice with 7 days survival (n = 3) and 28 days
survival (n = 3), XPro1595-treated SCI mice with 7 days
survival (n = 3) and 28 days survival (n = 4), and
etanercept-treated SCI mice with 7 days survival (n = 4)
and 28 days survival (n = 5). In total, 1.5 cm of spinal
cord tissue centered on the injury was quickly removed,
flash-frozen in liquid nitrogen, and stored in RNAse-free
Eppendorf tubes at −80°C until further processing.
Protein extraction
Proteins were extracted as previously described [3]. Briefly,
samples were homogenized in RIPA buffer (0.01 M sodium
phosphate pH 7.2, 0.15 M NaCl, 1% NP40, 1% sodium
deoxycholate, 0.1% SDS, 2 mM EDTA) supplemented
with Roche complete protease inhibitor cocktail, mixed
end-over-end at 4°C for 30 minutes, and centrifuged at
14,000 rpm for 10 min at 4°C. The supernatants were
transferred to fresh tubes and stored at −80°C.
Protein quantification
Protein quantification was performed using DC Protein
Assay (Bio-Rad, Hercules, CA, USA).
Protein electrophoresis and transfer
Equal amounts of protein lysates were resolved by SDS-
PAGE on 10 or 15% gels and transferred to nitrocellulose
membrane (Bio-Rad).
Protein visualization
Following blocking in 5% non-fat milk in tris buffered
saline + Triton (TBS-T), membranes were probed overnight
at 4°C with one of the following antibodies: recognizing
glial fibrillary acidic protein (GFAP, 1:500, BD Pharmingen),
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calcium binding adapter molecule 1 (Iba1, 1:400, Wako),
myelin basic protein (MBP, 1:500, Millipore), toll-like
receptor 4 (TLR4, 1:200, Santa Cruz), and tumor necrosis
factor receptor 2 (TNFR2, 1:200, Santa Cruz). After exten-
sive washes in TBS-T, membranes were incubated with
horseradish peroxidase-conjugated secondary antibodies
(1:2,000, GE Healthcare for anti-mouse and anti-rabbit,
1:1,000, Jackson ImmunoResearch for anti-rat) for 30 min
at room temperature. Detection was performed with Super-
Signal West Pico chemiluminescent substrate (Thermo
Scientific). Quantification was performed using Quantity
One software from Bio-Rad. Blots were normalized using
either mouse anti-β-actin (1:500, Santa Cruz) or rabbit
anti-β-actin (1:1,000, Cell Signaling).
Immunostaining
Immunostaining for macrophage/microglia-specific Iba1
was performed on paraffin-embedded sections using
rabbit anti-Iba1 (#019-19741, Wako) (1:600) essentially
as described in Dissing-Olesen et al. [37]. Sections were
counterstained with Toluidine blue. All sections were
stained at the same time.
Immunofluorescent staining
Immunofluorescent staining for GFAP was performed
on paraffin-embedded sections using mouse anti-human
GFAP-Alexa Fluor® 488 (A21282, Life Technologies)
(1:400) essentially as described in Clausen et al. [38].
Estimation of the total number of Iba1+ cells 7 days
after SCI
Using an approximated stereological counting technique
[3,39], we estimated the total number of Iba1+ cells in
the spinal cord 7 days after injury in mice treated epidu-
rally with either XPro1595 (n = 6), etanercept (n = 5), or
saline (n = 4). Cells with a clearly identifiable Toluidine
blue-stained nucleus in conjunction with a detectable
immunohistochemical signal were counted on approxi-
mately 7 sections centered on the lesion site and separated
by 150 μm from each animal, using a × 100 objective
and a 2,470 μm2 frame area stepping 150 μm/150 μm
in the XY-position using the New Computer Assisted
Stereological Toolbox (NewCAST) from Visiopharm
(Hoersholm, Denmark). The total number (N) of cells in
each animal was estimated using the formula: Estimate of
N = ∑Q ⋅ (1/ssf) ⋅ (1/asf) ⋅ (1/tsf), where 1/tsf is the thick-
ness sampling fraction (1/tsf = 1), 1/ssf is the sampling
section fraction (1/ssf = 10), and 1/asf is the area sampling
fraction (22,500/2,470) as previously described [3,39]. Due
to variations in length of the longitudinally cut spinal cord
sections, total cell numbers are given as number of Iba1+
cells/mm2. An average of 17 mm2 was estimated from
each animal.Densitometric analysis of Iba1+ cells 35 days after SCI
Due to the density of Iba1+ cells 35 days after SCI we
were unable to systematically perform stereological esti-
mations of the total number of Iba1+ cells at this time
point. Therefore, we performed a densitometric analysis
on spinal cord sections from mice treated epidurally
with either saline (n = 4), XPro1595 (n = 5), or etanercept
(n = 5) using Image J analysis software (NIH) as per direc-
tions of the Image J developers (http://rsb.info.nih.gov/ij)
and as described before [40]. Photo documentation was
done using an Olympus BX51 microscope with an
Olympus DP73 camera connected to a PC setup with
the Olympus CellSens software. All TIFF files were
grayscaled (8 bits) using Adobe Photoshop CS5 for
Mac, pictures imported as group pictures (17 sections
per animal) into Image J, and background subtracted.
Each section was delineated using the polygon selection
tool and the densitometry measured across the section was
estimated using the Log10(mean value/255) calculation.
Data analysis
Comparisons were performed using repeated measures
two-way ANOVA or one-way ANOVA followed by Tukey’s
post-hoc test. Analyses were performed using Prism 4.0b
software for Macintosh (GraphPad Software). Statistical
significance was established for P <0.05.
Results
The effect of systemically administered anti-TNF therapy
on functional recovery after SCI
Previous studies have demonstrated that TNF is upregu-
lated in the cord following trauma or disease and that
it participates in secondary injury mechanisms [2,10].
Using a mouse model of multiple sclerosis, we and
others determined that XPro1595 was therapeutic and
neuroprotective when administered systemically [9,20].
Therefore, based upon these earlier studies, we investi-
gated whether systemically administered XPro1595 would
improve functional recovery and reduce tissue damage in
a mouse model of traumatic SCI. In this study, animals
were randomly assigned to three different groups: saline
(vehicle), XPro1595, or etanercept. These drugs were
delivered s.c. within 30 min of injury and then again
every 3 days for 8 weeks. To test whether subcutaneous
administration of either XPro1595 or etanercept affected
functional recovery after SCI, locomotor performance
in the open field was recorded on day 1 and day 3 and
then weekly for 8 weeks, and scored with the BMS. We
determined there were no differences between any of the
treatment groups (final BMS ± SEM: saline: 5.3 ± 0.5;
XPro1595: 5.6 ± 0.6; and etanercept: 5.4 ± 0.9; P = 0.64;
Figure 1A). Mice were also evaluated using catwalk
analysis at 4 and 8 weeks after SCI (Figure 1C). All
treatment groups displayed significant changes over
Figure 1 Systemically administered anti-TNF therapy does not affect motosensory functions or lesion size after SCI. (A) Analysis of Basso
Mouse Scale (BMS) scores in mice treated systemically every third day with either XPro1595, etanercept, or saline for 8 weeks (56 days) showed
comparable locomotor performance in the open field arena (P = 0.64), though all groups significantly improved their BMS score over time
(****P <0.0001, two-way repeated masures ANOVA). (B) Luxol fast blue stained thoracic spinal cord sections from mice treated with either saline,
XPro1595, or etanercept and allowed 8 weeks survival after SCI. Scale bar: 100 μm. (C) Catwalk analysis showing changes in front and hind limb
stride length and front- and hind limb base of support (BOS) over time after SCI. No difference was observed between saline-, XPro1595-, and
etanercept-treated mice; however, all mice displayed significant changes in stride length (**P <0.01 for hind limbs and *****P <0.0001 for front
limbs, respectively) and BOS on the front limbs (**P <0.01) over time. (D) Gridwalk analysis showing changes in the average number of foot falls errors
and average number of foot slips errors over time after SCI. No difference was observed between saline-, XPro1595-, and etanercept-treated mice;
however, all mice displayed significant changes over time both in foot falls errors (***P <0.001) and foot fall slips (***P <0.001). (E) Analysis
of thermal hyperalgesia after SCI showed no differences in latencies to remove left (P = 0.27) or right (P = 0.16) hind limbs after stimulation
between saline-, XPro1595-, or etanercept-treated mice. All mice did, however, display significant changes over time in the latency to remove
both the left and right hind limbs after stimulation (****P <0.0001).
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hind limbs (P <0.01), but no differences were observed
between the treatments (P >0.05). Base of support also
significantly changed over time for the forelimbs (P <0.01)
but not for the hind limbs (P = 0.72) (Figure 1C). Grid
walk analysis at 4 and 8 weeks after SCI also did not
show any differences between treatment groups when
investigating the average number of foot fall errors
(P = 0.33) and the average number of foot slip errors
(P = 0.74, Figure 1D); however, we did observe SCI-
induced changes in both foot fall errors and foot slip
errors over time (P <0.001 for both).Histological evaluation of the injured cords 8 weeks
after SCI (Figure 1B) did not reveal any differences in
lesion size between groups. Importantly, we found no
significant differences in total body weight after SCI
between the different groups (P = 0.43, data not shown),
though all three groups displayed significant changes in
total body weight over time (P <0.0001).
The effect of centrally administered anti-TNF therapy on
functional recovery after SCI
These results were surprising because we and others had
previously determined that the systemic administration of
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sclerosis [9,20]. Numerous studies have reported that
TNF, mRNA, and protein, accumulate in the injured cord
within hours of injury and persist for several weeks
[10,41]. However, macrophages, the principal source of
systemic TNF, do not accumulate in the injured cord
in significant numbers for at least 72 h post trauma
[10,42,43]. Based upon these data and the failure of
systemically delivered XPro1595 to improve functional
recovery, we reasoned that TNF produced within the
injured cord by microglia, astrocytes, and other cell types
may facilitate tissue destruction and that targeting this
source of TNF may be required to promote functional
recovery. To test this hypothesis, we delivered either
XPro1595 or etanercept for 3 days directly to the lesion
epicenter following SCI and quantified changes in motor
performance. Using the BMS in the open field test,
we determined that compared to saline or etanercept,
XPro1595-treated mice exhibited a dramatic and signifi-
cant improvement in functional recovery (Figure 2A). Our
BMS data was supported by rung walk analysis (Figure 2B),
where XPro1595-treated mice displayed significantly
fewer mistakes compared to both saline- (P <0.01) and
etanercept-treated (P <0.05) mice. In contrast, we found
no differences in thermal hyperalgesia using the plantar
test (Figure 2C), where all groups displayed similar paw
withdrawal latency times after SCI. Latency times did,
however, change over time after SCI in all three groups
(P <0.0001). Histological analysis of the injured cords
35 days after SCI showed significantly smaller lesions in
XPro1595-treated mice compared to both saline- and
etanercept-treated mice (Figure 2D and E). Interestingly,
there was no change in GFAP expression, indicating that
inhibiting soluble TNF did not alter this one indicator of
reactive astrogliosis (Figure 2F).
Centrally administered XPro1595 improves general
activity and reduces anxiety-like behaviors following SCI
We noticed that mice treated with XPro1595 directly to
the cord, in general, looked healthier and exhibited more
exploratory activity and movement when in their home
cages. To address this formally, we performed open-field
analysis of SCI mice treated with saline, XPro1595, or
etanercept at 35 days post-injury, with observers blinded
to the treatment groups, to measure changes in general
activity and anxiety. We found no differences in the total
distance travelled in the open field, nor in the speed at
which the mice travelled, suggesting that XPro1595 or
etanercept do not affect overall activity levels (Figure 3A
and B). However, mice treated with XPro1595 spent
significantly more time in the center of the testing area
compared to both saline- and etanercept-treated mice
(Figure 3C) and displayed significantly more zone changes
(Figure 3D), suggesting less anxiety in XPro1595-treatedmice. The number of droppings between groups was
not different (Figure 3E). Both XPro1595- and etanercept-
treated mice displayed an increased number of groomings
compared to saline-treated mice (Figure 3F). Finally, most
of the XPro1595-treated mice were capable of rearing
at least once during testing, whereas none of the
etanercept- or saline-treated mice were capable of rearing
(data not shown).
Anti-TNF therapy affects microglial/macrophage
responses after SCI
Iba1 is often used as a marker to measure microglial and
macrophage activation and accumulation following injury
or disease to the central nervous system (CNS). Therefore,
we investigated whether our treatment strategies regulated
Iba1 expression and used this as a surrogate marker for
cell activation and accumulation in the cord. Western
blotting for Iba1 (Figure 4A) revealed a significant SCI-
induced increase in Iba1 expression in all treatment
groups both 7 days and 28 days after SCI, likely reflecting
activation of resident microglia and infiltration of macro-
phages. At 7 days after SCI, Iba1 expression was more
pronounced in saline-treated mice compared to both
XPro1595- and etanercept-treated mice, suggesting that
anti-TNF therapy decreases microglial activation and/or
macrophage infiltration. However, this increase in Iba1
expression in saline-treated mice was not reflected in
significantly increased numbers of Iba1+ cells in saline-
treated mice (Figure 4B, upper graph), suggesting that
microglial/macrophage activation was less pronounced in
Xpro1595- and etanercept-treated mice. At 28 days, Iba1
expression remained elevated in all three groups compared
to naive mice; in saline- and etanercept-treated mice to a
similar extent as at 7 days, and with a further increase in
XPro1595-treated mice (Figure 4A). This was also reflected
in comparable Iba1 protein expression 35 days after SCI in
all three groups of mice (Figure 4B, lower graph).
XPro1595-treatment sustains MBP expression possibly
through the upregulation of TNFR2 and TLR4 expression
in the lesioned spinal cord
Previous studies from our group and others have deter-
mined that improvements in functional recovery are
strongly correlated with enhanced myelin preservation
[3,8,9,32]. To address whether XPro1595 had similar
effects, we performed western blot analysis for MBP, a
marker for myelin integrity, in naive and injured mice.
We determined that at 7 days post-contusion there was
more MBP in the XPro1595 group relative to etanercept-
treated mice (Figure 5A). At 7 days after SCI, there was
no difference in MBP levels between XPro1595-treated
and naive controls. At 28 days post-contusion there
was a significant reduction in MBP in all treatment
groups compared to at 7 days after SCI and naive mice
Figure 2 Centrally administered XPro1595 improves motor functions and decreases lesion size after SCI. (A) Analysis of BMS scores in
mice treated centrally for three consecutive days with either saline, XPro1595, or etanercept showed that XPro1595-treated mice significantly
improved their BMS score from 3 to 35 days after SCI compared to both saline- and etanercept-treated mice (*P <0.05 and ***P <0.001, two-way
repeated measures ANOVA). All groups of mice significantly improved their BMS score over time (***P <0.001). (B) Rung walk analysis showed
that XPro1595-treated mice significantly decreased their number of mistakes compared to saline- and etanercept-treated mice (*P <0.05 and
**P <0.01). (C) Thermal stimulation using the Hargreave’s test showed no differences in latency time to withdraw paws between saline-, XPro1595-, and
etanercept-treated mice. All mice decreased their latency to remove their paws over time after SCI (****P <0.0001). (D) Luxol fast blue stained thoracic
spinal cord sections from mice treated with either saline, XPro1595, or etanercept and allowed 35 days survival after SCI. Scale bar: 100 μm. (E) Analysis
of lesion volumes 35 days after SCI showed that the lesion size was significantly smaller in XPro1595-treated mice compared to both saline- and
etanercept-treated mice (one-way ANOVA, followed by Tukey’s test). (F) Representative thoracic spinal cord sections from saline-, XPro1595-, and
etanercept-treated mice stained for anti-GFAP allowed 35 days survival. Scale bar: 100 μm. (G) Quantification of GFAP protein expression in spinal
cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. Data are normalized to β-actin protein expression. Results,
expressed as percent of control, are the mean ± SEM of three animals per group. *P <0.05, **P <0.01, and ***P <0.001 versus control by one-way
ANOVA with Tukey’s test.
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for this, we investigated TNFR2 and TLR4, two known
receptor signaling pathways implicated in positively influen-
cing myelin expression following CNS injury or disease
[3,9,44]. Using western blot analysis, we determined that
TNFR2 expression remained unchanged in XPro1595-
treated mice 7 days after SCI, whereas TNFR2 expression
decreased significantly in both saline- and etanercept-
treated mice (Figure 5B). At 28 days post-injury, TNFR2
levels were not statistically different from naive controls inany of the treatment groups. In a similar fashion, XPro1595
significantly increased TLR4 expression at 7 days after SCI
compared to the other treatment groups (Figure 5C). At
28 days after SCI, TLR4 levels were significantly reduced
compared to at 7 days after SCI. These data suggest that
inhibiting solTNF signaling within the first 3 days after SCI
promotes signaling through TNFR2 and TLR4, resulting in
reduced myelin loss and significant functional recovery.
GAP43 levels were not altered after SCI within the lesion
site (Figure 5D).
Figure 3 Open field test analysis of SCI mice treated centrally with anti-TNF therapy for three consecutive days and allowed 35 days of
survival after SCI. (A,B) Analysis of locomotor activity in mice treated centrally with either saline, XPro1595, or etanercept and allowed 35 days
survival after SCI showed that all mice travelled a similar distance (A) at comparable speeds (B) in the open field test. (C,D) Analysis of anxiety-related
behavior in the open field test showed that XPro1595-treated mice displayed decreased anxiety-related behavior represented by increased center/
perimeter ratio (C) and increased number of zone changes into the perimeter and center area (D). (E,F) The number of droppings (E) was comparable
in all groups of mice, whereas the number of groomings was increased both in XPro1595- and etanercept-treated mice compared to saline-treated
mice. *P <0.05 and **P <0.01, one-way ANOVA followed by Tukey’s test.
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In this study, we investigated the therapeutic potential of
two biologic inhibitors of TNF, XPro1595 and etaner-
cept, in a mouse model of traumatic SCI. XPro1595 is a
specific inhibitor of solTNF and therefore preferentially
disrupts signaling through TNFR1, without affecting
tmTNF signaling through TNFR2, whereas etanercept
non-specifically inhibits both solTNF and tmTNF and
thus signaling through TNFR1 and TNFR2. Our results
show that systemic administration of either XPro1595 or
etanercept by subcutaneous injection failed to improve
functional recovery and reduce tissue damage in our
mouse SCI model. In contrast, central administration of
XPro1595 but not etanercept significantly improved
functional recovery and reduced tissue damage, as shown
by smaller lesion sizes.The findings of a lack of effect of systemically adminis-
tered XPro1595 were unanticipated as we and others have
previously demonstrated that systemic administration of
XPro1595 significantly improved clinical scores, reduced
axonal damage, and promoted remyelination in myelin
oligodendrocyte glycoprotein-induced experimental EAE,
a mouse model of multiple sclerosis [9,20]. The apparent
discrepancy may be related to the fact that in multiple
sclerosis and EAE, inflammation is a more slowly evolving
sequence of events resulting from the activation of sys-
temically circulating, peripheral immune cells and their
infiltration into the CNS and subsequent attack on targets
within the CNS. In multiple sclerosis, this could evolve
over months to years before clinical symptoms develop,
and in EAE this process usually develops within the first
two weeks before clinical symptoms appear and continues
Figure 4 Changes in Iba1 protein expression following central anti-TNF treatment after SCI. (A) Quantification of Iba1 protein expression
in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. Data are normalized to β-actin protein expression.
Representative experiments are shown. Results, expressed as percent of control, are the mean ± SEM of three animals per group. #P <0.05
versus XPro1595 and etanercept; *P <0.05, **P <0.01, and ***P <0.001 versus control by one-way ANOVA with Tukey’s test. (B) Representative
low magnification photomicrographs of thoracic spinal cord sections from saline-, XPro1595-, and etanercept-treated mice allowed 7 and 35 days
survival after SCI and representative high magnification photomicrographs from saline-treated mice allowed 7 and 35 days survival and stained for
anti-Iba1. Estimation of the total number of Iba1+ cells 7 days after SCI (upper graph) and densitometric analysis of Iba1+ cells 35 days after SCI (lower
graph) displayed no difference in microglial/macrophage numbers between the different treatment groups. Scale bars: low magnification: 100 μm
and high magnification: 10 μm.
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in SCI, the initial and very acute inflammatory response is
primarily mediated by activated cells endogenous to the
spinal cord (such as microglia and astrocytes) or from the
leakage of inflammatory cytokines through the disrupted
blood-spinal cord barrier at the site of injury, because
peripheral blood leukocytes (such as neutrophils, macro-
phages, and T-cells) do not arrive in significant numbers
for days to weeks after the injury [2,10]. Microglia and
astrocytes have the capacity to secrete and respond to
numerous immunoregulatory cytokines such as TNF.
For example, previous studies have shown that TNF is
significantly elevated in the spinal cord within hours of
injury [2,8,10,45]. This acute elevation of TNF may be
toxic and hence systemically applied inhibitors may not
effectively neutralize elevated levels of CNS-derived TNF
before it can initiate damage. Interestingly, TNF has beendemonstrated to synergize with glutamate to promote
significant damage following SCI [46,47]. Therefore,
together with the induced vascular reactions that might
compromise the effective delivery of systemically delivered
substances after the impact, it is not surprising that
systemic therapies that are therapeutic in EAE may not be
efficacious in traumatic SCI. Indeed, when we delivered
XPro1595 or etanercept directly to the injured cord for
three consecutive days and evaluated improvements in
functional recovery and tissue damage, we determined
that XPro1595, but not etanercept, significantly improved
hind limb motor function as measured by significant im-
provements in BMS and rung walk tests, and reduced tis-
sue damage. These data demonstrate that selectively
inhibiting signaling of solTNF, possibly through TNFR1,
is neuro/glia protective and that inhibition of signaling
through both TNFR1 and TNFR2 is not protective. This
Figure 5 Changes in MBP, TNFR2, TLR4, and GAP43 protein expression following central anti-TNF treatment after SCI. (A) Quantification
of MBP protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (B) Quantification of
TNFR2 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (C) Quantification of
TLR2 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (D) Quantification of
GAP43 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. Data are normalized
to β-actin protein expression. Representative experiments are shown. Results, expressed as percent of control, are the mean ± SEM of three
animals per group. *P <0.05, **P <0.01, ***P <0.001, and ****P <0.0001 by one-way ANOVA with Tukey’s test.
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required for functional recovery and tissue repair. These
data also suggest that centrally elevated levels of solTNF,
rather than leukocyte-derived solTNF, is cytotoxic and
should be targeted for therapy following SCI.
The role of TNF in secondary SCI is supported by
numerous reports, including the observation that TNF
is significantly elevated in the cord within 1 h of injury
and that the anti-inflammatory cytokine IL-10 significantly
improves functional recovery and reduces SCI-induced
TNF [10]. This study further determined that SCI-induced
monocyte/macrophage-derived TNF was not detected
until 3 days post-injury and that levels in the cord were
significantly elevated within 1 h following traumatic SCI,
supporting our contention that elevated levels of TNF,
possibly solTNF, within the spinal cord at early time
points (e.g., within the first 24 h) are primarily due to
synthesis by CNS-derived cells [10]. One of the mecha-
nisms through which the acute production of solTNF is
suggested to be cytotoxic is though synergistic interactionswith glutamate [46,47]. These studies directly demonstrate
that TNF exacerbates glutamate-mediated cell death
in part through induced trafficking of GluR2-lacking
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors (AMPARs) to neuronal plasma membranes.
Interestingly, TNF-induced AMPAR trafficking has been
shown to occur within 1 h of SCI and to be ameliorated
through TNF inhibition [47], supporting the hypothesis of
involvement of CNS-derived TNF in AMPAR trafficking
and pathology after SCI.
There is a rich literature discussing the involvement of
TNF and other inflammatory cytokines in behaviors
such as anxiety and depression [48,49], and evidence
from clinical trials using anti-TNF biologic therapies for
psoriasis and rheumatoid arthritis patients demonstrated
that treatment caused significant changes in mood
[13,50]. Elevated levels of TNF and other inflammatory
mediators and their association with anxiety or depression-
like behaviors are generally studied in models of acute or
chronic stress; however, TNF and TNFR1 knock out mice
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phenotype [51]. We reasoned that traumatic SCI is indeed
a stressful stimuli and would be expected to induce
anxiety-like behaviors in injured mice. In support of this
hypothesis there are reports of anxiety and depression
in patients with spinal cord injury [52,53]. In fact, our
data show that inhibition of solTNF dramatically reduces
SCI-induced anxiety-like behaviors compared to saline-
and etanercept-treated mice. These data strongly suggest
that inhibiting solTNF may be a viable therapeutic strategy
for improving quality of life of persons suffering from
chronic SCI, and that this can be achieved without
compromising the patient’s innate immune response,
which is the case with current anti-TNF therapies [54,55].
The improvements in functional recovery observed in
our XPro1595-treated mice could be due in part to the
significant reduction in tissue damage and enhanced
myelin integrity, as measured by lesion volume analysis
and increased MBP expression. In the present study, we
observed significantly more MBP protein in Xpro1595-
treated animals at 7 days post-injury but by 28 days
post-injury levels had normalized between all treatment
groups. Therefore, improvements in functional recovery
at more chronic time intervals are likely due to a myriad
of factors such as enhanced tissue preservation, reduced
axonal injury, enhanced remyelination, and improved
vascularization. Recent in vivo and in vitro studies have
demonstrated that remyelination and neuroprotection are
dependent upon signaling through TNFR2 [9,20,21,56,57].
In support of this, we observed a significant increase in
TNFR2 expression in SCI mice treated with XPro1595
compared to etanercept-treated animals. Another im-
portant mediator of myelin integrity is TLR4, which
has been shown to promote oligodendrocyte progenitor
cell proliferation and to support oligodendrogenesis
[44,58]. Our data demonstrate that there is significantly
more TLR4 expression in XPro1595-treated mice. Col-
lectively, these data suggest that modulating the local
inflammatory response by inhibiting solTNF enhances
myelin integrity and improves functional recovery in
part through upregulation of TNFR2 and TLR4. Evi-
dence for TNFR2 signaling as an important regulator of
angiogenesis has recently been documented [59]. Using
TNFR2 null mice it was demonstrated that TNFR2 sig-
naling reduces hypoxia-mediated cell death and promotes
revascularization.Conclusions
Inhibiting solTNF within the cord immediately following
injury is therapeutic for traumatic SCI, whereas inhibiting
solTNF systemically is not. This study highlights the
importance of centrally-derived solTNF in the patho-
physiology of traumatic SCI.Abbreviations
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